JMP Securities Reiterates Market Outperform on Mirati Therapeutics, Maintains $58 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Mirati Therapeutics (NASDAQ:MRTX) and maintained a $58 price target.
September 28, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirati Therapeutics has received a reiterated Market Outperform rating from JMP Securities, with a maintained price target of $58.
The reiterated Market Outperform rating and maintained price target by JMP Securities indicates a positive outlook for Mirati Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100